Bildkälla: Stockfoto

Xspray Pharma Q2 2023: Defining quarters ahead - Redeye

Redeye updates on Xspray Pharma following its Q2 2023 report. Focus remains on the litigation and the FDA process with Dasynoc, we leave our comments and aside minor fine-tuning maintain our view of the case.

Redeye updates on Xspray Pharma following its Q2 2023 report. Focus remains on the litigation and the FDA process with Dasynoc, we leave our comments and aside minor fine-tuning maintain our view of the case.
Börsvärldens nyhetsbrev
ANNONSER